<DOC>
	<DOCNO>NCT01725555</DOCNO>
	<brief_summary>This prospective , randomize , open-label , Phase I , crossover study assess effect food bioavailability AXL1717 include patient advance malignant tumor</brief_summary>
	<brief_title>A Study Assess Effect Food Bioavailability IGF-1R Inhibitor AXL1717 Patients With Advanced Malignant Tumors</brief_title>
	<detailed_description>This randomize , crossover , open label , phase I study assess effect food bioavailability AXL1717 advance cancer patient . A single , oral dose AXL1717 administer patient two occasion 7-day apart , random order : overnight fast ( fast treatment ) high-fat moderate-fat breakfast ( fed treatment ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Be inform nature study provide write informed consent 2 . At least 18 year age 3 . Histologically confirm diagnosis advance solid hematological malignancy amenable standard treatment . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 optimization analgesic 5 . Life expectancy ≥ 3 month 6 . Hematology value : blood leukocyte count ≥ 3.0 x 109/L , blood absolute neutrophil count ≥ 1.5 x 109/L , blood platelet count ≥ 100 x109/L , hemoglobin ≥ 100 g/L ( transfusion allow ) 7 . Clinical chemistry value : plasma total bilirubin level ≤ 1.5 time upper limit `` normal '' range ( ULN ; i.e . reference ) , plasma AST ALT ≤ 1.5 x ULN ( ≤5 time liver metastasis document ) plasma creatinine ≤ 1.5 x ULN 8 . 12lead ECG normal tracing ; change clinically significant require medical intervention 1 . Ongoing infection major recent ongoing disease , accord Investigator , pose unacceptable risk patient 2 . Known primary secondary central nervous system malignancy . ( Patients symptom suggestive possible CNS metastasis headache , dizziness focal neurological deficit undergo CT MRI brain rule CNS metastasis . Patients CNS symptom need CT MRI brain . ) 3 . Grade 3 high constipation within past 28 day grade 2 constipation within past 14 day randomization . ( Patients grade 2 constipation within past 14 day could rescreened constipation decrease ≤ grade 1 optimal management constipation . ) 4 . Impairment gastrointestinal ( GI ) function , GI cancer GI disease may significantly alter absorption AXL1717 5 . Coexisting uncontrolled medical condition , include active cardiac disease ( unstable angina , myocardial infarction within 6 month , New York Heart Association Class III/IV congestive heart failure ) , significant dementia 6 . Hepatic impairment indicate abnormality transaminases and/or alkaline phosphatase ( AST and/or ALT &gt; 1.5 × upper limit normal concomitant alkaline phosphatase &gt; 2.5 × upper limit normal , ≤5 time liver metastasis document ) 7 . Major surgical procedure within 4 week prior randomization 8 . Use potent inhibitor CYP2C9 ( e.g . Fluconazole ) 3 week prior first administration investigational product 9 . Women child bear potential ( WOCBP ) consent use acceptable method contraception ( i.e . two follow oral contraception , barrier contraception , intrauterine device ) . For purpose study , WOCBP include female experienced menarche , undergone tubal ligation , postmenopausal . Post menopause define : amenorrhea ≥ 12 consecutive month without another cause . 10 . Women breastfeed positive pregnancy test screen 11 . Current participation investigational clinical trial administration investigational agent within 4 week study drug administration 10 halflives investigational agent , whichever longer . Patients unresolved investigational treatmentrelated AEs may participate . 12 . Known suspected hypersensitivity AXL1717 13 . Lack suitability participation trial , reason , judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>